Refine
Year of publication
Document Type
- Article (40)
- Book (2)
- Conference Proceeding (2)
- Preprint (2)
Has Fulltext
- yes (46)
Is part of the Bibliography
- no (46)
Keywords
- Diagnostik (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Früherkennung (2)
- Mammakarzinom (2)
- Nachsorge (2)
- Richtlinie (2)
- breast cancer (2)
- diagnosis (2)
- follow‑up (2)
- guideline (2)
- screening (2)
- ALK-rearranged NSCLC (1)
- AML (1)
- APRI (1)
- Acute myeloid leukemia (1)
- Antibiotic steward-ship (1)
- Antibiotics (1)
- Autorschaft (1)
- BFIS (1)
- Bleeding (1)
- CDI (1)
- CT (1)
- CVID (1)
- Chemotherapy (1)
- Cleanliness level (1)
- Colon capsule endoscopy (1)
- Complementation rate (1)
- DYT1 (1)
- Death rates (1)
- Dopamine (1)
- ESBL (1)
- Early goal-directed therapy (1)
- Enterobacteriaceae (1)
- European Society for Immunodeficiencies (ESID) (1)
- Evidence-based guidelines (1)
- FIB-4 (1)
- Fevers (1)
- Fibrotest (1)
- German PID-NET registry (1)
- HBV (1)
- HCV (1)
- HIV (1)
- Heavy Ion Experiments (1)
- Hepatocellular carcinoma (1)
- Hepatotoxicity (1)
- Hospitals (1)
- INR (1)
- IgG substitution therapy (1)
- Incomplete colonoscopy (1)
- Induction chemotherapy (1)
- Infection (1)
- Intensive care unit (1)
- International normalized ratio (1)
- Inverse kinematics (1)
- Isoscalar giant resonances (1)
- LFP (1)
- Literarischer Stil (1)
- Literaturwissenschaft (1)
- Liver cancer (1)
- Liver cirrhosis (1)
- Liver enzymes (1)
- Low volume prep (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Mortality (1)
- Moviprep (1)
- Multidrug-resistant organisms (1)
- Neutropenia (1)
- PID prevalence (1)
- PKD (1)
- PKD/IC (1)
- PRRT2 (1)
- Phospho-soda (1)
- PillCamColon2 (1)
- Point-of-care testing (1)
- Polyps (1)
- Psoriasis vulgaris (1)
- Sepsis-bundle (1)
- Storage ring (1)
- Survival (1)
- TOR1A (1)
- TP53 mutation status (1)
- Transient elastography (1)
- Treatment (1)
- Two-hit hypothesis (1)
- VRE (1)
- acoustic radiation force impulse imaging (1)
- adenocarcinoma (1)
- axions (1)
- cART (1)
- co-infection (1)
- computed tomography (1)
- critical care unit (1)
- critical ill patients (1)
- dark matter experiments (1)
- direct-acting antivirals (1)
- familial infantile epilepsy (1)
- fibrotest (1)
- hemiplegic migraine (1)
- hepatic fibrosis (1)
- hepatitis C virus (1)
- insulin resistance (1)
- interferon regulatory factor 9 (IRF9) (1)
- lung cancer (1)
- mechanical accuracy (1)
- non-invasive fibrosis assessment (1)
- phantom study (1)
- phenotypic spectrum (1)
- point shear wave elastography (1)
- primary immunodeficiency (PID) (1)
- registry for primary immunodeficiency (1)
- robot-guided stereotaxy (1)
- sepsis (1)
- sequential ALK-inhibitor therapy (1)
- solar physics (1)
- stereotactic frame (1)
- stereotactic neurosurgery (1)
- transient elastography (1)
- tumor microenvironment (TME) (1)
- type I interferons (IFNs) (1)
- versican (VCAN) (1)
- white and brown dwarfs (1)
Institute
- Medizin (26)
- Physik (9)
- Frankfurt Institute for Advanced Studies (FIAS) (7)
- Informatik (4)
- Biochemie und Chemie (2)
- Biochemie, Chemie und Pharmazie (2)
- Extern (2)
- Informatik und Mathematik (2)
- MPI für Biophysik (2)
- ELEMENTS (1)
Pathogenic variants in PRRT2, encoding the proline-rich transmembrane protein 2, have been associated with an evolving spectrum of paroxysmal neurologic disorders. Based on a cohort of children with PRRT2-related infantile epilepsy, this study aimed at delineating the broad clinical spectrum of PRRT2-associated phenotypes in these children and their relatives. Only a few recent larger cohort studies are on record and findings from single reports were not confirmed so far. We collected detailed genetic and phenotypic data of 40 previously unreported patients from 36 families. All patients had benign infantile epilepsy and harbored pathogenic variants in PRRT2 (core cohort). Clinical data of 62 family members were included, comprising a cohort of 102 individuals (extended cohort) with PRRT2-associated neurological disease. Additional phenotypes in the cohort of patients with benign sporadic and familial infantile epilepsy consist of movement disorders with paroxysmal kinesigenic dyskinesia in six patients, infantile-onset movement disorders in 2 of 40 individuals, and episodic ataxia after mild head trauma in one girl with bi-allelic variants in PRRT2. The same girl displayed a focal cortical dysplasia upon brain imaging. Familial hemiplegic migraine and migraine with aura were reported in nine families. A single individual developed epilepsy with continuous spikes and waves during sleep. In addition to known variants, we report the novel variant c.843G>T, p.(Trp281Cys) that co-segregated with benign infantile epilepsy and migraine in one family. Our study highlights the variability of clinical presentations of patients harboring pathogenic PRRT2 variants and expands the associated phenotypic spectrum.
In non-hadronic axion models, which have a tree-level axion-electron interaction, the Sun produces a strong axion flux by bremsstrahlung, Compton scattering, and axiorecombination, the "BCA processes." Based on a new calculation of this flux, including for the first time axio-recombination, we derive limits on the axion-electron Yukawa coupling gae and axion-photon interaction strength ga using the CAST phase-I data (vacuum phase). For ma <~ 10 meV/c2 we find ga gae < 8.1 × 10−23 GeV−1 at 95% CL. We stress that a next-generation axion helioscope such as the proposed IAXO could push this sensitivity into a range beyond stellar energy-loss limits and test the hypothesis that white-dwarf cooling is dominated by axion emission.
Objective: Nationwide data on the epidemiology, treatment characteristics, and long-term outcome of severe traumatic brain injury (TBI) in Germany is not yet existing. Neurosurgeons from the German Neurosurgery Society (DGNC) and traumatologists from the German Trauma Society (DGU), therefore, joined forces in 2016 to conceptualize a TBI module for the well-established Trauma Register of the DGU (TR-DGU). Here, we report how this “German National TBI registry (GNTR)” has been developed, implemented, and tested in a recently completed pilot period.
Methods: The conception and implementation process of the GNTR from August 2016 to February 2019 is described, and results of its 23-months long pilot period from February 2019 to December 2020 are presented. For the pilot period, TBI patients were prospectively enrolled at nine neurosurgical and traumatological hospitals across Germany. Inclusion criteria were treatment on the ICU ≥ 24h, or an ISS score ≥ 16. A variety of clinical, imaging, and laboratory parameters were collected, and the GOSE score was used to assess the outcome at discharge and 6- and 12 months follow-up.
Results: Details on the structure and dataset of the GNTR as well as milestones and pitfalls during its conception and implementation, are outlined. During the pilot period, a total of 264 TBI patients were enrolled. Their demographic characteristics, clinical, imaging, and radiological findings, and their early mortality and functional outcome are described. Furthermore, factors associated with an unfavorable outcome (GOSE 1-4) are assessed using uni- and multivariate regression analyses. Finally, problems and future directions of the GNTR are discussed.
Conclusion: The pilot period of the GNTR offers a first glance at the current epidemiology and treatment characteristics of TBI patients in Germany. More importantly, they show how a national TBI registry yielding high-quality prospective data can be developed, implemented, and tested within four years
Patients with acute myeloid leukemia (AML) are often exposed to broad-spectrum antibiotics and thus at high risk of Clostridioides difficile infections (CDI). As bacterial infections are a common cause for treatment-related mortality in these patients, we conducted a retrospective study to analyze the incidence of CDI and to evaluate risk factors for CDI in a large uniformly treated AML cohort. A total of 415 AML patients undergoing intensive induction chemotherapy between 2007 and 2019 were included in this retrospective analysis. Patients presenting with diarrhea and positive stool testing for toxin-producing Clostridioides difficile were defined to have CDI. CDI was diagnosed in 37 (8.9%) of 415 AML patients with decreasing CDI rates between 2013 and 2019 versus 2007 to 2012. Days with fever, exposition to carbapenems, and glycopeptides were significantly associated with CDI in AML patients. Clinical endpoints such as length of hospital stay, admission to ICU, response rates, and survival were not adversely affected. We identified febrile episodes and exposition to carbapenems and glycopeptides as risk factors for CDI in AML patients undergoing induction chemotherapy, thereby highlighting the importance of interdisciplinary antibiotic stewardship programs guiding treatment strategies in AML patients with infectious complications to carefully balance risks and benefits of anti-infective agents.
Die Fundmeldungen in Band 34 von Botanik und Naturschutz in Hessen stammen von: Dirk Bönsel, Martin De Jong, Klaus Dühr, Uta Engel, Benjamin Feller, Christian Feuring, Thomas Gregor, Arthur Händler, Karsten Horn, Diemut Klärner, Julia Kruse, Eric Martiné, Hasko Friedrich Nesemann, Kai Uwe Nierbauer, Uwe Raabe, Susanne Raehse, Felix Reischmann, Bernd Sauerwein, Petra Schmidt, Fabian Schrauth, Christof Nikolaus Schröder, Helmut Siebert, Michael Thieme, Otto Wacker und Rüdiger Wittig.
Aim: To evaluate the ability of PillCamColon2 to visualize colonic segments missed by incomplete optical colonoscopy (OC) and to assess the diagnostic yield.
Methods: This prospective multicentre study included 81 patients from nine centres who underwent second-generation colon capsule endoscopy (CCE) following incomplete OC performed by an experienced gastroenterologist (> 1000 colonoscopies). Patients with stenosis were excluded. According to patient preferences, CCE was performed the following day (protocol A) after staying on clear liquids and 0.75 L Moviprep in the morning or within 30 d after new split-dose Moviprep (protocol B). Boosts consisted of 0.75 L and 0.25 L Moviprep, and phospho-soda was given as a rescue if the capsule was not excreted after seven hours.
Results: Seventy-four patients were analysed (51% of them in group A; 49% in group B). Bowel cleansing was adequate in 67% of cases, and CCE could visualize colonic segments missed by incomplete colonoscopy in 90% of patients under protocol A and 97% of patients under protocol B (P = 0.35, n.s.). Significant polyps including adenocarcinoma were detected in 24% of cases. Detection rates for all polyps and significant polyps per patient were similar in both protocols. Polyps were found predominantly in the right colon (86%) in segments that were not reached by OC. Extracolonic findings - such as reflux esophagitis, suspected Barrett esophagus, upper GI-bleeding, gastric polyps, gastric erosions and angiectasia - were detected in eight patients. PillCamColon2 capsule was retained in the ileum of one patient (1.4%) without symptoms and removed during an uneventful resection for unknown Crohn’s disease that was diagnosed as the cause of anemia, which was the indication for colonoscopy. CCE was well tolerated. One patient suffered from self-limiting vomiting after consuming the phospho-soda.
Conclusion: Second-generation CCE using a low-volume preparation is useful after incomplete OC, and it allows for the detection of additional relevant findings, but cleansing efficiency could be improved.